GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCryst Pharmaceuticals Inc (STU:BO1) » Definitions » 14-Day RSI

BioCryst Pharmaceuticals (STU:BO1) 14-Day RSI : 58.76 (As of Dec. 12, 2024)


View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-12-12), BioCryst Pharmaceuticals's 14-Day RSI is 58.76.

The industry rank for BioCryst Pharmaceuticals's 14-Day RSI or its related term are showing as below:

STU:BO1's 14-Day RSI is ranked worse than
79.78% of 1523 companies
in the Biotechnology industry
Industry Median: 46.92 vs STU:BO1: 58.76

Competitive Comparison of BioCryst Pharmaceuticals's 14-Day RSI

For the Biotechnology subindustry, BioCryst Pharmaceuticals's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCryst Pharmaceuticals's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's 14-Day RSI falls into.



BioCryst Pharmaceuticals  (STU:BO1) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioCryst Pharmaceuticals  (STU:BO1) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


BioCryst Pharmaceuticals 14-Day RSI Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCryst Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

BioCryst Pharmaceuticals Headlines

No Headlines